Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Nurandociguat (BAY3283142) new tablet, Nurandociguat new
Nurandociguat · 1 trial · 1 indication
The incidence of treatment-emergent adverse events will be summarized.
| Arm | Type | Description |
|---|---|---|
| Nurandociguat Arm | EXPERIMENTAL | Participants receive nurandociguat plus 0.4 mg nitroglycerin spray |
| Placebo Arm | PLACEBO_COMPARATOR | Participants receive placebo matching nurandociguat plus 0.4 mg nitroglycerin spray |
| Name | Type | Description |
|---|---|---|
| Nitroglycerin spray | DRUG | 0.4 mg sublingual spray |
| Nurandociguat | DRUG | Tablet, oral |
| Placebo | DRUG | Tablet matching nurandociguat, oral |
Inclusion Criteria: * Participant must be 40 to 80 years of age inclusive at the time of signing the informed consent * Participants with stable CAD defined by coronary artery stenosis in any of the 3 main coronary vessels greater than 50 percent documented by coronary angiography within the last 3...
Nurandociguat is an investigational small molecule being developed for stable coronary artery disease. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied to understand its safety and effects when taken alone or with nitroglycerin in people with coronary artery disease.
Nurandociguat is being developed by Bayer AG, a multinational pharmaceutical company. Bayer's stock is traded over-the-counter under the ticker BAYRY. The company is conducting clinical research to evaluate the drug's safety and tolerability in patients with stable coronary artery disease.
Nurandociguat is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 1 trial is designed to assess the drug's safety, tolerability, and how it interacts with nitroglycerin in patients with stable coronary artery disease.
Nurandociguat is being studied in a Phase 1 clinical trial registered as NCT07431294. This randomized, double-blind, placebo-controlled study is investigating the safety and effects of Nurandociguat when taken with nitroglycerin in people with coronary artery disease. The trial plans to enroll 36 participants in Bulgaria and Germany.
Yes, Nurandociguat is also known as BAY3283142. The drug is being developed by Bayer AG under this code name. In clinical trial registrations, it may be referred to as Nurandociguat or BAY3283142. The current Phase 1 study evaluates the safety of this compound in patients with stable coronary artery disease.
The mechanism of action for Nurandociguat has not been disclosed in the available clinical trial information. It is a small molecule being investigated for its potential effects in stable coronary artery disease. The ongoing Phase 1 trial focuses on safety and drug interactions rather than efficacy or mechanism.